Still brutally undervalued! I wrote in detail in another post...

Still brutally undervalued! I wrote in detail in another post about it coming re-rating (was long overdue) as its long term prospectus have changed permanently (permanently relieved from ongoing losses and funding requirements of medtech business) and heading to profitability faster than most think. Very large orders booked in ready for delivery in FY2020. Find me another stock on ASX who is held this tightly and trading less than book value and emerging & better prospects for future with Dividends likely to resumed from FY2020.